| Autor: |
Marina Vian Ossick, Karen Linares Ferrari, Igor Nunes-Silva, Fernandes Denardi, Leonardo Oliveira Reis |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Acta Cirúrgica Brasileira, Vol 34, Iss 12 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
0102-8650 |
| DOI: |
10.1590/s0102-865020190120000007 |
| Popis: |
Abstract In the muscle invasive bladder cancer (MIBC) standard of care treatment only patients presenting a major pathological tumor response are more likely to show the established modest 5% absolute survival benefit at 5 years after cisplatin-based neoadjuvant chemotherapy (NAC). To overcome the drawbacks of a blind NAC (i.e. late cystectomy with unnecessary NAC adverse events) with potential to survival improvements, preclinical models of urothelial carcinoma have arisen in this generation as a way to pre-determine drug resistance even before therapy is targeted. The implantation of tumor specimens in the chorioallantoic membrane (MCA) of the chicken embryo results in a high-efficiency graft, thus allowing large-scale studies of patient-derived “tumor avatar”. This article discusses a novel approach that exploits cancer multidrug resistance to provide personalized phenotype-based therapy utilizing the MIBC NAC dilemma. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
